Key result
A 1-point higher cardiovascular health score at 1 year post-transplant was not significantly associated with a reduced risk of composite adverse outcomes at 3 years (OR 0.95).
Why the study?
Pediatric heart transplant patients may be at risk for suboptimal cardiovascular health.
Does a higher cardiovascular health (CVH) score improve the composite adverse outcome of death, re-listing, CAV, or CKD in pediatric heart transplant patients?
Observational (n=110)
No
Does a higher cardiovascular health (CVH) score improve the composite adverse outcome of death, re-listing, CAV, or CKD in pediatric heart transplant patients?
Odds Ratio: 0.95 (95% CI 0.7–1.4)
Pediatric heart transplant patients generally have favorable cardiovascular health scores, though some metrics like glucose are worse than the general population, and no significant association was found between CVH score and adverse outcomes at 3 years in this small cohort.
No significant association observed; leaves open CVH's prognostic role in pediatric heart transplant.
BACKGROUND: Ideal "cardiovascular health" (CVH)-optimal diet, exercise, nonsmoking, BMI, BP, lipids, and glucose-is associated with healthy longevity in adults. Pediatric heart transplant (HT) patients may be at risk for suboptimal CVH. METHODS: Single-center retrospective study of HT patients 2003-2014 who survived 1 year post-transplant. Five CVH metrics were collected at listing, 1, 3 and 5 years post-transplant (diet and exercise were unavailable). CVH was scored by summing individual metrics: ideal = 2, intermediate = 1, and poor = 0 points; total scores of 8-10 points were considered high (favorable). CVH was compared between HT patients and the US pediatric population (GP) utilizing NHANES 2007-2016. Logistic regression was performed to examine the association of CVH 1 year post-transplant with a composite adverse outcome (death, re-listing, coronary vasculopathy, or chronic kidney disease) 3 years post-transplant. RESULTS: We included 110 HT patients (median age at HT: 6 years [range 0.1-21]) and 19,081 NHANES participants. CVH scores among HT patients were generally high at listing (75%), 1 (74%), 3 (87%) and 5 (76%) years post-transplant and similar to GP, but some metrics (e.g., glucose) were worse among HT patients. Among HT patients, CVH was poorer with older age and non-Caucasian race/ethnicity. Per 1-point higher CVH score, the demographic-adjusted OR for adverse outcomes was 0.95 (95% CI, 0.7-1.4). CONCLUSIONS: HT patients had generally favorable CVH, but some metrics were unfavorable and CVH varied by age and race/ethnicity. No significant association was detected between CVH and adverse outcomes in this small sample, but study in a larger sample is warranted.
No takes yet. Share an insight, caveat, or question.
Bogle et al. (2022) conducted an observational in Pediatric heart transplant (n=110). Cardiovascular health (CVH) score vs. Lower CVH score was evaluated on Composite adverse outcome (death, re-listing, coronary vasculopathy, or chronic kidney disease) at 3 years post-transplant (OR 0.95, 95% CI 0.7-1.4). A 1-point higher cardiovascular health score at 1 year post-transplant was not significantly associated with a reduced risk of composite adverse outcomes at 3 years (OR 0.95).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: